Want to see UPB full AI Analyst Report?
Top Page
Upstream Bio, Inc.
(NASDAQ:UPB)
Select Model
Select Model
Rating:49Neutral
Price Target:
$4.00
▼(-43.90% Downside)
Action:Reiterated
Date:10/13/26
The score is held back primarily by heavy losses and significant cash burn with minimal revenue, implying ongoing reliance on external funding. Technicals are weak due to a strong downtrend, partially offset by very oversold momentum readings. A supportive balance sheet (low debt) and a positive Phase 3 program update provide some upside support, but valuation remains challenged because the company is loss-making and offers no dividend.
Positive Factors
Low Leverage
Very low leverage and positive equity provide financial flexibility while the company advances its pipeline. Limited debt reduces interest and refinancing pressure, allowing more capital to remain available for research, clinical development, and operating needs over the next several quarters.
Negative Factors
Heavy Cash Burn
Substantial recurring cash consumption means the company is using capital rapidly before generating meaningful operating inflows. Unless spending moderates or revenue scales, continued development is likely to require external funding, which can reduce financial flexibility and create dilution pressure.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Very low leverage and positive equity provide financial flexibility while the company advances its pipeline. Limited debt reduces interest and refinancing pressure, allowing more capital to remain available for research, clinical development, and operating needs over the next several quarters.
Read all positive factors
Upstream Bio, Inc. (UPB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$228.40M
Dividend YieldN/A
Average Volume (3M)763.61K
Price to Earnings (P/E)―
Beta (1Y)1.21
Revenue Growth15.98%
EPS Growth-40.75%
CountryUS
Employees75
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.90
Shares Outstanding54,771,040
10 Day Avg. Volume1,106,602
30 Day Avg. Volume763,607
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)4.30
Price to Sales (P/S)512.30
P/FCF Ratio-10.97
Enterprise Value/Market Cap0.51
Enterprise Value/Revenue37.13
Enterprise Value/Gross Profit37.72
Enterprise Value/Ebitda-0.75
Forecast
1Y Price Target
$22.25Price Target Upside212.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-2.87
Revenue Forecast (FY)$2.71M
Upstream Bio, Inc. Business Overview & Revenue Model
Company Description
Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a ...
Upstream Bio, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
67
Positive
Cash Flow
21
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.16M | 2.85M | 2.37M | 2.38M | 1.21M |
| Gross Profit | 3.11M | 2.85M | 2.37M | 2.38M | 1.21M |
| EBITDA | -156.30M | -143.25M | -62.72M | -20.48M | -23.86M |
| Net Income | -156.50M | -143.44M | -62.81M | -20.54M | -23.87M |
Balance Sheet | |||||
| Total Assets | 281.17M | 353.77M | 481.72M | 117.20M | 18.48M |
| Cash, Cash Equivalents and Short-Term Investments | 261.31M | 341.51M | 470.45M | 109.81M | 17.05M |
| Total Debt | 954.00K | 1.27M | 1.83M | 45.00K | 94.00K |
| Total Liabilities | 10.21M | 14.00M | 11.87M | 240.32M | 124.63M |
| Stockholders Equity | 270.96M | 339.77M | 469.85M | -123.13M | -106.16M |
Cash Flow | |||||
| Free Cash Flow | -136.34M | -133.28M | -59.68M | -38.07M | -19.10M |
| Operating Cash Flow | -136.34M | -133.28M | -59.17M | -37.93M | -19.02M |
| Investing Cash Flow | 165.29M | -93.48M | -59.48M | -82.84M | -82.00K |
| Financing Cash Flow | 4.99M | 2.44M | 418.91M | 129.55M | 9.96M |
Upstream Bio, Inc. Technical Analysis
Negative
7.13
Price Trends
6.03
Negative
6.55
Negative
11.08
Negative
Market Momentum
-0.44
Positive
24.30
Positive
17.15
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UPB, the sentiment is Negative. The current price of 7.13 is above the 20-day moving average (MA) of 5.07, above the 50-day MA of 6.03, and below the 200-day MA of 11.08, indicating a bearish trend. The MACD of -0.44 indicates Positive momentum. The RSI at 24.30 is Positive, neither overbought nor oversold. The STOCH value of 17.15 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for UPB.
Upstream Bio, Inc. Risk Analysis
Upstream Bio, Inc. disclosed 80 risk factors in its most recent earnings report. Upstream Bio, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Upstream Bio, Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | $358.41M | -3.79 | -46.54% | 1.29% | -82.95% | -49.04% | |
49 Neutral | $228.40M | -1.44 | -48.40% | ― | 15.98% | -40.75% | |
48 Neutral | $272.24M | -15.50 | -5.76% | ― | ― | 93.45% | |
48 Neutral | $280.20M | -4.32 | -41.69% | ― | 6280.00% | -212.54% | |
47 Neutral | $422.35M | -3.68 | -196.63% | ― | 20.83% | 73.89% | |
41 Neutral | $53.27M | -0.46 | -89.11% | ― | 10.02% | 39.66% |
* General Sector Average
UPB
Upstream Bio, Inc.
3.55
-16.43
-82.23%
ARCT
Arcturus Therapeutics
12.03
-9.22
-43.39%
RCKT
Rocket Pharmaceuticals
2.30
-1.97
-46.14%
ABEO
Abeona Therapeutics
4.52
-0.83
-15.51%
EDIT
Editas Medicine
2.45
-1.15
-31.89%
CRBU
Caribou Biosciences
0.47
-1.97
-80.74%
Upstream Bio, Inc. Corporate Events
Business Operations and StrategyProduct-Related Announcements
Upstream Bio Outlines Phase 3 Plans for Verekitug
Positive
Sep 1, 2026
On September 1, 2026, Upstream Bio announced detailed plans for pivotal Phase 3 trials of its lead drug candidate, verekitug, in severe asthma and chronic rhinosinusitis with nasal polyps, following productive End-of-Phase 2 discussions with the U...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.